Navigation Links
First clinical trials successfully completed on potent new hepatitis C drug
Date:9/3/2010

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

Completion of the initial phase (phase 1a) of trials of INX-189, discovered and first prepared by researchers at Cardiff University's Welsh School of Pharmacy in 2008, means the chances of it becoming an approved medicine have significantly improved.

Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation in western countries. The current treatment involves two drugs ribavirin and interferon, which has to be given as an injection. Side effects are often severe and lead to patients failing to complete the treatment.

Professor Chris McGuigan of the Welsh School of Pharmacy, academic lead on the project, said: "This is still a very early stage of the trials process but none the less a significant development. Successfully completing phase 1a demonstrates that the drug is safe, with no drug-related side effects at all in a single dose of 100mg.

"The efficiency of drug release in this study has also confirmed that one single dose a day is most likely enough in treating the virus.

"We believe that INX-189 offers the possibility of more potency against Hepatitis, more rapid action in the liver, and fewer side effects than existing treatments."

In 2008, laboratory tests showed INX-189 killed 90 per cent of the virus at very low (nanomolar) concentration, making it the most potent compound of its kind developed to date.

US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, has announced it is looking forward to a second trial (phase 1b), which would evaluate the compound's effectiveness in Hepatitis C patients.

Cardiff University and Inhibitex filed a patent on INX-189 earlier
'/>"/>

Contact: Lowri Jones
joneslc3@cardiff.ac.uk
Cardiff University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Almost 1 in 3 First-Time Deliveries Now Via C-Section
2. For the first time, researchers identify and isolate adult mammary stem cells in mice
3. Gold Standard/Elsevier first to launch state, federal controlled substance drug schedules
4. Southampton to conduct UKs first cochlear implant operation to give sound in both ears
5. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
6. K-State professors book is first to explore Two-Spirit literature in Northwest native groups
7. Deaf, hard-of-hearing students perform first test of sign language by cell phone
8. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
9. Doctors hard to find for patients in Massachusetts first for-profit health plan
10. Scientists develop the first model for investigating the origins of testicular cancer in humans
11. UCLA scientists for the first time identify a cell-of-origin for human prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... ... One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... the first things FDA investigators will look at during an inspection. Yet, ...
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital ... The center invites all those prospective joint-replacement patients, along with their friends and family ... month, with Monday classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing program of ... its options. Already an industry leader because of its use of iPad technology ... latest successful trends in helping people to overcome addiction and live healthy, productive ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... says more programs needed for transition to adult health care ... arthritis need more help and information when they approach adulthood ... new study shows. , The study, led by Peter Scal ... of adolescents with arthritis received counseling on issues such as ...
... Drain NEW YORK, Jan. 13 New York Blood ... City, Long Island, Hudson Valley and New Jersey) have ... demand for blood (needed for emergency care and surgery) ... donation have been below forecast. Blood supplies have ...
... Goldring smiles as she shows a visitor photos she,s taken ... The demonstration comes more than 20 years after Goldring, a ... colleagues began work on a "seeing machine" that can allow ... the Internet, view the face of a friend and much ...
... New Version Increases Physician AccessSUNNYVALE, Calif., Jan. 13 ... version of the Pathwork(R) Tissue of Origin Test ... (FFPE) tissue specimens. This molecular diagnostic test, which ... origins, is now available as a service through ...
... 13, 2009) The American Journal of Nursing ... healthcare publications of 2008 with an announcement today of ... 15 separate categories appear in the journal,s January issue. ... of controversial consumer health topics and nursing industry issues ...
... Fla., Jan. 13 Zassi Medical,Evolutions(R), a privately ... and development, today announced the launch of e-Zassi(TM) ... the medical,device industry by streamlining diligence, collaboration and ... an exclusive array of,intelligent Web-based applications. , ...
Cached Medicine News:Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5Health News:MIT develops camera for the blind 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 3Health News:American Journal of Nursing announces 2008 Book of the Year Awards 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 3
(Date:7/27/2015)... July 20, 2015 ... the addition of the "Cardiometabolic Drug News ... Afrezza,s discounted pricing is in line with our ... to the product,s commercial appeal. However, contraindications, side ... from gaining a sizeable share of the fast-acting ...
(Date:7/27/2015)... N.H. , July 27, 2015  Linear ... incredibly intricate machines, requiring not only adequate space ... vaults for their operation. Inherent to the size ... a linear accelerator or the addition of a ... hospital. Suspending operations risks interruption of patient treatment: ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ) has ... Receptors Market: Global Industry Analysis, Size, Share, Growth, ... to their offering. The global ... assay type, therapeutic area, and geography. Based on ... into six major segments: cAMP assays, calcium level ...
Breaking Medicine Technology:Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Pharma NV/SA, a rapidly growing pharmaceutical company specialising in ... Veeva CRM to support its salesforce in Belgium. Pharco ... application that was both pharma-specific and easily adaptable. The ... for the global pharma and biotech industry. ...
... New Zealand health technology company Medtech Global, ... collaborated to develop an electronic health information solution ... medical records of visiting international MedicAlert members in ... first" the long term vision for the solution ...
Cached Medicine Technology:Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 2Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 3Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 2Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 3
... The SYNCHRON CX5-S workstation ... electrolyte testing, targeted to the ... than 200 samples per day. ... the CX5-S is easy to ...
... the high-volume lab, the SYNCHRON LX4201 simplifies ... up to 2,880 tests per hour. By ... SYNCHRON LX4201 with broad menu, speed and ... come to expect from Beckman Coulter-innovative, reliable ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... the power of the LX2000 Series ... resources without compromising testing quality.Plus, when ... LX20 PRO, you get advanced features ... other chemistry analyzer, including closed tube ...
Medicine Products: